Elusys Therapeutics

It received a Biomedical Advanced Research and Development Authority development contract in 2010 worth up to 143 million dollars, and Health Canada later approved Anthim. In December 2023 Elusys Holdings acquired Elusys from NightHawk Biosciences, assuming about 40 million dollars of liabilities and manufacturing commitments; the transaction closed on 27 December 2023.

The current federal procurement is HHS contract 75A50324C00006, a sole-source firm-fixed-price purchase of Anthim for anthrax treatment and the Strategic National Stockpile, awarded on 1 May 2024, extended through 31 December 2028 and valued at about 124.5 million dollars on the federal contract record. The headquarters city was not confirmed in the sources read.

Owned by Elusys Holdings since 27 December 2023, which acquired the company from NightHawk Biosciences

Parent: Elusys Holdings (bought from Scorpius Holdings, Dec 2023) (checked)

• https://en.wikipedia.org/wiki/Elusys_Therapeutics
• https://www.sec.gov/Archives/edgar/data/1476963/000155837023019910/nhwk-20231219xex99d1.htm
• https://www.prnewswire.com/news-releases/elusys-receives-contract-for-up-to-143-million-from-the-us-federal-government-to-fund-advanced-development-of-anthimr-a-new-treatment-for-anthrax-80617792.html
• https://www.highergov.com/contract/75A50324C00006/
• https://elusys.com/anthim-2/

• Headquarters city: not confirmed (sheet has none).
• Contract value comes from an aggregator copy of the federal record.
• The sheet says Elusys Holdings is independent private since December 2023; the acquirer's own ownership is not independently documented.